HAVN Life Sciences Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a HAVN.CN research report →
Companywww.havnlife.com
HAVN Life Sciences Inc. , a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp.
- CEO
- Tim Moore
- IPO
- 2020
- HQ
- Richmond, BC, CA
Price Chart
Valuation
- Market Cap
- $1.15M
- P/E
- -0.01
- P/S
- 4.17
- P/B
- 0.04
- EV/EBITDA
- -0.02
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 32.44%
- Op Margin
- -3548.44%
- Net Margin
- -8117.81%
- ROE
- -274.69%
- ROIC
- -277.90%
Growth & Income
- Revenue
- $276.47K · 0.00%
- Net Income
- $-22,443,548 · 26.13%
- EPS
- $-5.25 · 38.02%
- Op Income
- $-9,810,466
- FCF YoY
- 23.69%
Performance & Tape
- 52W High
- $0.03
- 52W Low
- $0.03
- 50D MA
- $0.03
- 200D MA
- $0.03
- Beta
- -0.66
- Avg Volume
- 0
Get TickerSpark's AI analysis on HAVN.CN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our HAVN.CN Coverage
We haven't published any research on HAVN.CN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate HAVN.CN Report →